This situation mirrors that of CD133/PROM1 (Figure 3), so we speculate that the apparently low tumor-wide expression of ABCG2 and ICAM4 is because they are robustly expressed only in CD133+ cells, which constitute a minor fraction of the tumor cells. Here, ABCG2 is linked to neoplasm.